Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Author: Benzinga Newsdesk | May 15, 2024 04:27pm
Aytu BioPharma (NASDAQ:
AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
Posted In: AYTU